NEW YORK, Dec. 12, 2010 /PRNewswire/ — Pfizer Inc. (NYSE:
PFE) announced that Prevenar 13* (Pneumococcal polysaccharide
conjugate vaccine [13-valent, adsorbed]) was introduced into the
first childhood immunization program for pneumococcal disease (PD)
in the developing world under the auspices of the Advance Market
Commitment (AMC) when Nicaragua launched its program today.
The AMC is an innovative program which involves
private-public partnerships to help make newer vaccines available
on a sustainable, affordable and accelerated basis to the least
developed countries.
(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)
“Pfizer remains steadfast in its commitment to accelerate global
access to its vaccines and medicines; public-private partnerships
such as those that underpin the AMC are a great example of how to
make critical progress in that area,” says Mark Swindell,
president, Pfizer Vaccines. “It truly is historic to see a
new vaccine such as Prevenar 13 launched in a developing country
within one year of its introduction in the U.S. and Europe, given
the previous average 15-year gap between introduction of new
vaccines in developed and developing countries.”
Prevenar 13 provides coverage against the 13 most prevalent
invasive pneumococcal disease-causing strains (1, 3, 4, 5, 6A, 6B,
7F, 9V, 14, 18C, 19A, 19F, and 23F) in infants and young
children worldwide. Prevenar 13 is the only pneumococcal
conjugate vaccine available under the AMC that is prequalified by
the World Health Organization (WHO) for use in children through 5
years of age and to help prevent pneumonia caused by the 13
serotypes contained in the vaccine.
About the AMC
In March 2010, Pfizer entered into a 10-year agreement to
provide Prevenar 13 to infants and young chil
‘/>”/>
SOURCE
